GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Cyclically Adjusted PS Ratio

Vanda Pharmaceuticals (FRA:VM4) Cyclically Adjusted PS Ratio : 1.33 (As of May. 21, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-21), Vanda Pharmaceuticals's current share price is €5.00. Vanda Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €3.75. Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 1.33.

The historical rank and industry rank for Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:VM4' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.82   Med: 6.25   Max: 14.05
Current: 1.26

During the past years, Vanda Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 14.05. The lowest was 0.82. And the median was 6.25.

FRA:VM4's Cyclically Adjusted PS Ratio is ranked better than
82.84% of 507 companies
in the Biotechnology industry
Industry Median: 5.55 vs FRA:VM4: 1.26

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vanda Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.756. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €3.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vanda Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.59 4.64 4.65 1.90 1.00

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.60 1.03 1.00 0.95

Competitive Comparison of Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Vanda Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5.00/3.75
=1.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Vanda Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.756/131.7762*131.7762
=0.756

Current CPI (Mar. 2024) = 131.7762.

Vanda Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.236 100.560 0.309
201409 0.339 100.428 0.445
201412 0.275 99.070 0.366
201503 0.490 99.621 0.648
201506 0.585 100.684 0.766
201509 0.595 100.392 0.781
201512 0.683 99.792 0.902
201603 0.693 100.470 0.909
201606 0.742 101.688 0.962
201609 0.788 101.861 1.019
201612 0.824 101.863 1.066
201703 0.788 102.862 1.010
201706 0.837 103.349 1.067
201709 0.773 104.136 0.978
201712 0.833 104.011 1.055
201803 0.733 105.290 0.917
201806 0.751 106.317 0.931
201809 0.770 106.507 0.953
201812 0.844 105.998 1.049
201903 0.800 107.251 0.983
201906 0.958 108.070 1.168
201909 0.990 108.329 1.204
201912 0.997 108.420 1.212
202003 0.957 108.902 1.158
202006 1.003 108.767 1.215
202009 0.927 109.815 1.112
202012 1.000 109.897 1.199
202103 0.932 111.754 1.099
202106 0.990 114.631 1.138
202109 1.045 115.734 1.190
202112 1.052 117.630 1.179
202203 0.974 121.301 1.058
202206 1.072 125.017 1.130
202209 1.158 125.227 1.219
202212 1.036 125.222 1.090
202303 1.017 127.348 1.052
202306 0.739 128.729 0.756
202309 0.631 129.860 0.640
202312 0.720 129.419 0.733
202403 0.756 131.776 0.756

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vanda Pharmaceuticals  (FRA:VM4) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vanda Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (FRA:VM4) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines